[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583724":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":24,"locations":27,"responsibleParty":40,"collaborators":24,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":24,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":66,"whyStopped":24,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Lahore General Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tacrolimus","ACTIVE_COMPARATOR","Patient of Limited vitiligo less than 20% BSA will be treated with topical tacrolimus and narrowband UVB",[13],"Drug: Tacrolimus",{"label":15,"type":10,"description":16,"interventionNames":17},"Calcipotriol","Calcipotriol is a vitamin D analogue that will act as immunomodulator",[18],"Drug: Calcipotriol",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Tacrolimus is calcineurin inhibitor that will act as immunomodulator",[9],null,{"type":21,"name":15,"description":16,"armGroupLabels":26,"otherNames":24},[15],[28],{"facility":29,"status":24,"city":30,"state":31,"zip":24,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":24},"Lahore general.hospital","Lahore","Punjab Province","Pakistan","PK",{"type":35,"coordinates":36},"Point",[37,38],74.35071,31.558,{"lat":38,"lon":37},{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"SPONSOR_INVESTIGATOR","Dr ayesha wahid","Awahid","100583724","early-phase-1-comparison-of-efficacy-and-safety-of-narrowband-uvb-with-01-tacrolimus-vs-narrowband-uvb-with-0005-calcipotriol-in-treatment-of-vitiligo-100583724",false,"NCT06880042","COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO","NB-UVB","Inclusion Criteria:\n\n\\- Localized vitiligo Age 15 to 70years Body surface upto 20% Stable more than 3 months\n\nExclusion Criteria:\n\n* • Pregnant or lactating female patients.\n\n  * Skin malignancy or any other malignant skin condition.\n  * Photo induced or photo aggravated dermatosis like (SLE, photodermatitis, rosacea, psoriasis, pemphigus vulgaris) along with vitiligo.\n  * Prior history of allergy to tacrolimus or calcipotriol.\n  * Other form of treatment for vitiligo within at least 1 month.",true,"ALL","15 Years","70 Years",{"count":56,"type":57},60,"ESTIMATED","INTERVENTIONAL",[60],"EARLY_PHASE1","Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed",[63,9],"Vitiligo - Macular Depigmentation",[65],"Vitiligo","ENROLLING_BY_INVITATION","2025-06-23",{"date":69,"type":70},"2025-06-24","ACTUAL",{"date":72,"type":70},"2025-05-01",{"date":74,"type":57},"2025-08-30",{"name":42,"class":6},1]